Latest Press Releases

 
 

Aspyrian therapeutics inc. closes $15.1m as part of a series b-1 financing to support the advancement of its proprietary precision targeted therapy, rm-1929, to late stage clinical development and the progression of new proprietary immune oncology assets into the clinic

SAN DIEGO, July 19, 2017 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, has closed $15.1 million as part of a Series B-1 financing round expected to reach about $19 million...click here to continue reading

 

Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options

SAN DIEGO, April 27, 2017 /PRNewswire/ -- Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head & Neck Society meeting, April 27, in San Diego...click here to continue reading

 

 

Aspyrian Therapeutics Inc. closes a $40M Series B financing to advance the precision targeted cancer therapy, RM-1929, to late stage clinical development in recurrent head and neck cancer and other cancer areas.

SAN DIEGO, March 10, 2016 /PRNewswire/ -- Aspyrian Therapeutics Inc., a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform has secured $40 million as part of a Series B financing...click here to continue reading

 

 

Aspyrian Therapeutics Inc. Announces FDA Acceptance of an Investigational New Drug Application for RM-1929, a First-in-Class, Precision-Targeted Therapy for Cancer

SAN DIEGO, May 12, 2015 /PRNewswire/ -- Aspyrian Therapeutics Inc., a drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform, today announced the U.S. Food & Drug Administration (FDA) has accepted the Company's first Investigational New Drug (IND) application to begin clinical studies of RM-1929 for the treatment of patients with recurrent head and neck cancer...click here to continue reading

 

 

Aspyrian Therapeutics Inc. Closes $4.25M Series A Extension Financing to Support the Execution of Phase 1 Clinical Studies of the Precision Targeted Cancer Therapy, RM-1929, to Treat Late-Stage Recurrent Head and Neck Cancers

SAN DIEGO, July 27, 2015 /PRNewswire/ -- Aspyrian Therapeutics Inc., a clinical stage drug development company creating precision-targeted therapies to treat cancer based on its proprietary Photoimmunotherapy platform has secured $4.25 million as part of a Series A extension financing...click here to continue reading